Emerging market challenges no hindrance to pharma
Despite the challenges that emerging market present, such as intellectual property (IP) exposure and drug pricing controls, the pharma industry is not being deterred.
Archives for March 18, 2008
Applied Bio sequences a human genome for $60,000
Applied Biosystems has sequenced a human genome for just $60,000 in a project that significantly undercuts the $100,000 milestone achieved by the industry and setting the scene for a price war between DNA sequencing tool specialists.
Omnitrope Pen 5 ups the convenience factor
A new, more patient-friendly presentation of the growth hormone treatment Omnitrope (rDNA somatropin) has been launched in the US by Sandoz, the generics division of Swiss-based Novartis.
TMH autoinjector to reach US after FDA go-ahead
A disposable autoinjector that incorporates pre-filled syringes to allow injections to be safely undertaken by patients or non-clinicians has received FDA approval allowing its creators access to the lucrative US market.
Peptide Technologies extends synthesis range with new Tribute
Peptide Technologies showcased their latest rapid automated peptide synthesis equipment at Pittcon 2008, including a new product, the benchtop Tribute instrument.
Crucell, DSM hit 15g/L milestone with PER.C6 technology
Dutch biotech Crucell and its US partner DSM Biologics have achieved a record yield of 15 grams per litre with their PER.C6 cell line technology for the production of monoclonal antibodies and recombinant proteins.
Teva to invest $100m in Hungary
Israeli generics maker Teva will spend $100m to double its manufacturing capacity in Hungary, as the pharma global spread continues.